Novartis Looks To Expand Beovu’s Use And Move On From Safety Scare
Diabetic Macular Edema (DME) Filing Possible In 2021
New data for a further indication should help Novartis rebuild momentum for competitor to Eylea, but safety concerns could take years to overcome.
You may also be interested in...
A composite endpoint conceals Actemra’s lack of mortality benefit – while life-saving dexamethasone gets EMA endorsement.
The world is waiting for Moderna’s COVID-19 vaccine results, but meanwhile the company is exploring new avenues to secure long-term growth
Scotland’s investment in regenerative medicine is paying off with two promising start-ups, one targeting liver disease, the other oncology, launching within days of each other.